Silence Therapeutics (SLN) Share-based Compensation (2024 - 2026)
Silence Therapeutics recorded quarterly Share-based Compensation of $2.4 million in Q1 2026, up 2945.35% quarter-over-quarter from -$86000.0 in Q4 2025, and down 30.88% year-over-year from $3.5 million in Q1 2025.
Silence Therapeutics' Share-based Compensation history runs 3 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 30.88% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $7.0 million (down 55.62% YoY), while the FY2025 annual figure was $8.1 million, down 50.49% from the prior year.
- Share-based Compensation came in at $2.4 million for Q1 2026 at Silence Therapeutics, up from -$86000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2024 to a low of -$86000.0 in Q4 2025.
- A 3-year average of $3.0 million and a median of $3.5 million in 2025 frame the typical range for Share-based Compensation.
- On a YoY basis, Share-based Compensation climbed as much as 14.04% in 2025 and fell as far as 102.16% in 2025.
- Silence Therapeutics' Share-based Compensation stood at $4.0 million in 2024, then plunged by 102.16% to -$86000.0 in 2025, then surged by 2945.35% to $2.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, -$86000.0, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | 2.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.45 Mn |
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | -86,000.00 |
| Dec 31, 2025 | -86,000.00 |
| Sep 30, 2025 | 2.54 Mn |
| Sep 30, 2025 | 2.54 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Mar 31, 2024 | 4.12 Mn |